Apitolisib
- Generic Name
- Apitolisib
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O3S
- CAS Number
- 1032754-93-0
- Unique Ingredient Identifier
- 1C854K1MIJ
- Background
Apitolisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, and Endometrial Carcinoma, among others.
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT01485861
- Locations
- πΊπΈ
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
πΊπΈKaiser Permanente Medical Ctr, Honolulu, Hawaii, United States
π¨πΏVseobecna fakultni nemocnice v Praze, Praha 2, Czechia
Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01473316
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01455493
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01442090
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: GDC-0941 Matching PlaceboDrug: GDC-0980 Matching Placebo
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT01437566
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01332604
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT01301716
A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT01287091
- Locations
- πΊπΈ
Investigational Site, Austin, Texas, United States
Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01254526
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT00854152
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath